Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Solid Biosciences (SLDB)
:SLDB
Holding SLDB?
Track your performance easily
SLDB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $15.05
Previous CloseN/A
Volume1.97M
Average Volume (3M)473.34K
Market Cap
$129.85M
Enterprise Value$142.46M
Total Cash (Recent Filing)$37.66M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.91
Next Earnings
Mar 12, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.04
Shares Outstanding39,954,605
10 Day Avg. Volume741,014
30 Day Avg. Volume473,337
Standard Deviation0.33
R-Squared0.10
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)259.70
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue284.92
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.40
Forecast
1Y Price Target
$16.33Price Target Upside402.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Solid Biosciences News
Bulls Say, Bears Say
Bulls Say
Collaborative DevelopmentSolid announced a collaboration with Mayo Clinic to develop an AAV gene therapy platform for therapies to treat sudden cardiac death-predisposing genetic cardiomyopathies and channelopathies.
Innovative Treatment StrategyThe dual administration strategy of SGT-212, involving both intravenous infusion and MRI-guided injection, could effectively treat both neurological and cardiac symptoms of FA.
Regulatory SupportThe FDA has approved Solid Biosciences' IND application for SGT-212, a gene therapy for Friedreich's ataxia, showing regulatory support for the treatment.
Bears Say
Financial PerformanceThe company reported no revenue for 3Q24 and a net loss of $0.79 per share, compared to the consensus estimated net loss of 0.67.
Market SentimentSLDB has taken the largest hit due to doubts on microdystrophin gene therapy in DMD following a recent presentation and news article.
Project Termination RiskThere is downside risk to $4/share on a complete SGT-003 termination.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SLDB FAQ
What was Solid Biosciences’s price range in the past 12 months?
Solid Biosciences lowest stock price was $3.03 and its highest was $15.05 in the past 12 months.
What is Solid Biosciences’s market cap?
Solid Biosciences’s market cap is $129.85M.
When is Solid Biosciences’s upcoming earnings report date?
Solid Biosciences’s upcoming earnings report date is Mar 12, 2025 which is in 50 days.
How were Solid Biosciences’s earnings last quarter?
Solid Biosciences released its earnings results on Nov 06, 2024. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.668 by -$0.122.
Is Solid Biosciences overvalued?
According to Wall Street analysts Solid Biosciences’s price is currently Undervalued.
Does Solid Biosciences pay dividends?
Solid Biosciences does not currently pay dividends.
What is Solid Biosciences’s EPS estimate?
Solid Biosciences’s EPS estimate is -0.79.
How many shares outstanding does Solid Biosciences have?
Solid Biosciences has 39,954,605 shares outstanding.
What happened to Solid Biosciences’s price movement after its last earnings report?
Solid Biosciences reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.668. Following the earnings report the stock price went down -6.026%.
Which hedge fund is a major shareholder of Solid Biosciences?
Among the largest hedge funds holding Solid Biosciences’s share is Perceptive Advisors LLC. It holds Solid Biosciences’s shares valued at 48M.
---
Solid Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.33 (402.46% Upside)
$16.33 (402.46% Upside)
Blogger Sentiment
Bullish
SLDB Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.8%
Last 30 Days ▲ 26.2%
Last 30 Days ▲ 26.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-59.42%
12-Months-Change
Fundamentals
Return on Equity
-65.79%
Trailing 12-Months
Asset Growth
14.67%
Trailing 12-Months
Company Description
Solid Biosciences
Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy. It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Arnold, Annie Ganot and Gilad David Hayeem in March 2013 and is headquartered in Cambridge, MA.
---
SLDB Stock 12 Month Forecast
Average Price Target
$16.33
▲(402.46% Upside)
Technical Analysis
Adverum Biotechnologies
―
BioMarin Pharmaceutical
―
RegenXBio
―
Fate Therapeutics
―
Adaptimmune Therapeutics
―
Allogene Therapeutics
―
Best Analysts Covering SLDB
1 Year
---